Table 3.

Genetic analysis of African American patients with thrombotic microangiopathy and African American control subjects

Control subjectsTM patients with deficient VWCPP
n% abnormal (heterozygous/
homozygous)
n% abnormal (heterozygous/
homozygous)
Factor V G1691A 190 2  (3/0) 10 0   (0/0) > .99  
Factor II G20210A 191 1  (1/0) 10 0   (0/0) > .99 
MTHFR C677T 192 23-150 (3) 10 03-150  (0) > .99  
GP1a C807T 231 56  (102/28) 10 30   (3/0) .117 
PAI-1 4G/5G 202 83-150 (17) 10 203-150  (2) .222 
Control subjectsTM patients with deficient VWCPP
n% abnormal (heterozygous/
homozygous)
n% abnormal (heterozygous/
homozygous)
Factor V G1691A 190 2  (3/0) 10 0   (0/0) > .99  
Factor II G20210A 191 1  (1/0) 10 0   (0/0) > .99 
MTHFR C677T 192 23-150 (3) 10 03-150  (0) > .99  
GP1a C807T 231 56  (102/28) 10 30   (3/0) .117 
PAI-1 4G/5G 202 83-150 (17) 10 203-150  (2) .222 

All P values are from Fisher exact test.

F3-150

For MTHFR C677T and PAI-1 4G/5G, the abnormal is homozygous only; heterozygous individuals are classified as normal.

Close Modal

or Create an Account

Close Modal
Close Modal